Atlas.
Sign inStart free trial
ZBHNASDAQ · US

ZIMMER BIOMET HOLDINGS, INC.

Technology · Orthopedic, Prosthetic & Surgical Appliances & Supplies

TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
CEO
Ivan Tornos
Founded
—
IPO Date
—
HQ
Warsaw, IN, United States
Exchange
NYSE
Employees
n.a.

Share Price Performance

$84.17 ▼ 6.5%
Last (1 Jul 2026) · $84
Period High · $100.99
Period Low · $79.58
52W: $79.58 – $107.71

Key Metrics

Share Price
$84.17
-2.2% today
Market Cap
$16.7B
P / E
23.7x
EV / Revenue
2.9x
Revenue Growth
+7.2%
year-on-year
Gross Margin
—
Enterprise Value
$23.6B
52W High
$107.71
52W Low
$79.58
Avg Volume
1.9M
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
12 known institutional holders·$3.7B total on record·2026-Q1
BlackRock, Inc.
7.7%·$1.4B
State Street Corp
4.5%·$800M
Price T Rowe Associates Inc
4.0%·$723,335
Geode Capital Management, LLC
2.7%·$485M
Invesco Ltd.
1.8%·$326M
Dimensional Fund Advisors LP
1.1%·$201M
Northern Trust Corp
1.0%·$183M
Bank Of America Corp
0.8%·$140M
Goldman Sachs Group Inc
0.5%·$98M
Jpmorgan Chase & Co
0.4%·$73M
Fmr LLC
0.1%·$9M
Renaissance Technologies LLC
0.0%·$5M
Free Float
75.3%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for ZIMMER BIOMET HOLDINGS, INC.
OverviewZIMMER BIOMET HOLDINGS, INC. share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow ZIMMER BIOMET HOLDINGS, INC. generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsZIMMER BIOMET HOLDINGS, INC.'s complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityZIMMER BIOMET HOLDINGS, INC. executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsZIMMER BIOMET HOLDINGS, INC.'s annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for ZIMMER BIOMET HOLDINGS, INC., updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for ZIMMER BIOMET HOLDINGS, INC. aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersZIMMER BIOMET HOLDINGS, INC. valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for ZIMMER BIOMET HOLDINGS, INC. with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for ZIMMER BIOMET HOLDINGS, INC. — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial